

**PRESS RELEASE**


Source: Tokyo Institute of Technology, Center for Public Affairs and Communications

For immediate release:

Tokyo Institute of Technology research: **A new tumor suppressor gene for breast cancer in mice.**


(Tokyo, September 2016) **Researchers at Tokyo Institute of Technology revealed a role for an X-linked protein kinase Nrk in terminating the proliferation of mammary epithelial cells during pregnancy and thereby preventing breast tumorigenesis in mice.**

In recent years, the incidence of breast cancer has been increasing worldwide, and breast cancer is becoming a serious object of public concern. The onset of breast cancer is closely related to the sex hormone estrogen, and estrogen antagonists such as tamoxifen have been used as anti-breast cancer drugs. During pregnancy, the elevated blood estrogen level induces the proliferation of mammary epithelial cells, leading to the development of the mammary gland in preparation for lactation. The mammary epithelial cells eventually stop proliferation at late stages of pregnancy, impairment of which potentially results in breast tumorigenesis (Fig. 1). However, the regulatory mechanisms of mammary epithelial cell proliferation during pregnancy have been unclear.




**Fig. 1 Proliferation of mammary epithelial cells and breast cancer**

Nrk is a protein kinase encoded in the X chromosome. To study the Nrk function *in vivo*, Professor Masayuki Komada's group generated mutant mice with disrupted *Nrk* gene, making them unable to produce the Nrk protein. During maintenance of the mutant mouse colony, the researchers noticed that the *Nrk* mutant mice frequently exhibited breast tumors after repetitive pregnancy/parturition. The absence of tumors in virgin *Nrk* mutant mice strongly suggests that the tumorigenesis is closely related to the proliferation of mammary epithelial cells during pregnancy. Histopathological examinations showed that this breast tumor is a non-invasive, relatively benign cancer (Fig. 2). In addition, the tumor was positive for estrogen receptor alpha (ER alpha) and cell proliferation marker Ki67, and negative for receptor tyrosine kinase HER2/ErbB2, suggesting that it has features like luminal B type breast cancer in humans (Fig. 3).




**Fig. 2 Histological analysis of *Nrk* mutant breast tumor**




**Fig. 3 Subtype classification of *Nrk* mutant breast tumor**

In *Nrk* mutant mammary glands, dense clusters of ER alpha-positive mammary epithelial cells were sometimes observed at late stages of pregnancy, which may represent the “bud” of the breast tumor (Fig. 4). While *Nrk* expression was undetectable in the mammary glands of wild-type mice in non-pregnant conditions, it was detected at late stages of pregnancy. This suggests that *Nrk* is expressed in mammary epithelial cells late in pregnancy in order to terminate their proliferation. In addition, blood estrogen levels at late stages of pregnancy were found to be about two times higher in *Nrk* mutant mice than in wild-type mice, suggesting that *Nrk* is also involved in the regulation of synthesis or secretion of estrogen. In *Nrk* mutant mice, therefore, mammary tumorigenesis was proposed to be triggered by a combination of dysregulation of proliferation in mammary epithelial cells and excessive blood estrogen.



**Fig. 4 ER $\alpha$  expression of in *Nrk* mutant mammary epithelial cells**

Collectively, these results suggest that *Nrk* negatively regulates the estrogen-dependent proliferation of mammary epithelial cells, the disruption of which leads to breast tumors (Fig. 5). Humans have an ortholog of the murine *Nrk* gene, and considering that the gene expression pattern in breast tumor in *Nrk* mutant mice was similar to that in human luminal B breast cancer, the findings of this study may lead to further understanding of the mechanisms of human breast cancer suppression and to advances in its diagnosis and therapy.



**Fig. 5 Impaired regulation of mammary epithelial cell proliferation in *Nrk* mutant mice**

**【Reference】**

Authors: Yanagawa T<sup>1,2,3</sup>, Denda K<sup>1</sup>, Inatani T<sup>1</sup>, Fukushima T<sup>1,4</sup>, Tanaka T<sup>1</sup>, Kumaki N<sup>5</sup>, Inagaki Y<sup>2,3</sup>, and Komada M<sup>1,4</sup>,

Title of original paper: Deficiency of X-linked protein kinase Nrk during pregnancy triggers breast tumor in mice

Journal: *The American Journal of Pathology* DOI: 10.1016/j.ajpath.2016.06.005

Affiliations:

<sup>1</sup>Department of Biological Sciences, Tokyo Institute of Technology

<sup>2</sup>Center for Matrix Biology and Medicine, Tokai University

<sup>3</sup>Department of Regenerative Medicine, Tokai University

<sup>4</sup>Cell Biology Unit, Institute of Innovative Research, Tokyo Institute of Technology

<sup>5</sup>Department of Pathology, Tokai University

**Correspondence to:** [makomada@bio.titech.ac.jp](mailto:makomada@bio.titech.ac.jp)

**Contact**

Emiko Kawaguchi

Center for Public Affairs and Communications,

Tokyo Institute of Technology

[E-mail.media@jim.titech.ac.jp](mailto:E-mail.media@jim.titech.ac.jp)

+81-3-5734-2975

About Tokyo Institute of Technology

Tokyo Institute of Technology stands at the forefront of research and higher education as the leading university for science and technology in Japan. Tokyo Tech researchers excel in a variety of fields, such as material science, biology, computer science and physics. Founded in 1881, Tokyo Tech has grown to host 10,000 undergraduate and graduate students who become principled leaders of their fields and some of the most sought-after scientists and engineers at top companies. Embodying the Japanese philosophy of “monotsukuri,” meaning technical ingenuity and innovation, the Tokyo Tech community strives to make significant contributions to society through high-impact research.

Website: <http://www.titech.ac.jp/english/>